#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Czech Work­ing Group for Paediatric Gastroenterology and Nutrition guidelines for dia­gnostics and treatment of inflam­matory bowel diseases in children –  1stedition update


Authors: J. Bronský 1;  K. Beránková 1;  Z. Černá 2;  I. Čopová 1;  D. Ďuricová 3,4 ;  M. Durilová 5;  O. Hradský 1;  E. Karásková 6;  K. Mitrová 1,3 ;  J. Nevoral 1;  L. Poš 5;  J. Schwarz 2;  P. Szitányi 7;  R. Škába 5;  A. Šuláková 8;  J. Tuková 7
Authors place of work: Pediatrická klinika 2. LF UK a FN Motol, Praha 1;  Dětská klinika LF UK a FN Plzeň 2;  Klinické a výzkumné centrum pro střevní záněty ISCARE I. V. F. a.  s., Praha 3;  Farmakologický ústav, 1. LF UK a VFN v Praze 4;  Klinika dětské chirurgie 2. LF UK a FN Motol, Praha 5;  Dětská klinika LF UP a FN Olomouc 6;  Klinika dětského a dorostového lékařství 1. LF UK a VFN v Praze 7;  Klinika dětského lékařství LF OU a FN Ostrava 8
Published in the journal: Gastroent Hepatol 2017; 71(1): 11-18
Category:
doi: https://doi.org/10.14735/amgh201711

Summary

The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study.

The Editorial Board declares that the manuscript met the ICMJE „uniform requirements“ for biomedical papers.

Submitted:
20.10.2016

 Accepted:
30. 10. 2016


Zdroje

1. Ruem­mele FM, Veres G, Kolho KL et al. Consensus guidelines of ECCO/ ESPGHAN on the medical management of pediatric Crohn’s disease. J Crohns Colitis 2014; 8(10): 1179– 1207. doi: 10.1016/ j.crohns.2014.04.005.

2. Keil R, Was­serbauer M, Zádorová Z et al. Clinical monitoring: infliximab bio­similar CT-P13 in the treatment of Crohn’s disease and ulcerative colitis. Scand J Gastroenterol 2016; 51(9): 1062–– 1068. doi: 10.3109/ 00365521.2016.1149883.

3. Smits LJ, Derikx LA, de Jong DJ et al. Clinical outcomes fol­low­ing a switch from Remicade® to the bio­similar CT--P13 in inflam­matory bowel disease patients: a prospective observational cohort study. J Crohns Colitis 2016; 10(11): 1287– 1293.

4. Farkas K, Rutka M, Golovics PA et al. Ef­ficacy of infliximab bio­similar CT-P13 induction therapy on mucosal heal­ing in ulcerative colitis. J Crohns Colitis 2016; 10(11): 1273– 1278.

5. Gecse KB, Lovász BD, Farkas K et al. Ef­ficacy and Safety of the bio­similar infliximab CT-P13 treatment in inflam­matory bowel diseases: a prospective, multicentre, nationwide cohort. J Crohns Colitis 2016; 10(2): 133– 140. doi: 10.1093/  ecco-jcc/ jjv220.

6. Sieczkowska J, Jarzębicka D, Banaszkiewicz A et al. Switch­ing between infliximab originator and biosimilar in pae­-diatric patients with inflam­matory bowel disease. Preliminary observations. J Crohns Colitis 2016; 10(2): 127– 132. doi: 10.1093/ ecco-jcc/ jjv233.

7. Radin M, Sciascia S, Roccatel­lo D et al. Infliximab bio­similars in the treatment of inflam­matory bowel diseases: a systematic review. BioDrugs 2017; 31: 37. doi: 10.1007/ s40259-016-0206-1.

8. de Ridder L, Waterman M, Turner D et al. Use of bio­similars in paediatric inflam­matory bowel disease: a position statement of the ESPGHAN paediatric IBD Porto Group. J Pediatr Gastroenterol Nutr 2015; 61(4): 503– 508. doi: 10.1097/ mpg.000000 0000000903.

9. Singh N, Patel M, Rabizadeh S et al. Vedolizumab use in pediatric patients with inflam­matory bowel disease. Gastroenterology 2015; 148(4): S72. doi: 10.1016/ s0016-5085(15)30250-x.

10. Conrad MA et al. The use of vedolizumab for treatment of severe pediatric inflam­matory bowel disease. Gastroenterology 2015; 148(4): S72.

11. Mer­ras-Salmio L, Kolho KL. Golimumab therapy in six patients with severe pediatric onset Crohn disease. J Pediatr Gastroenterol Nutr 2016; 63(3): 344– 347. doi: 10.1097/ MPG.0000000000001165.

12. Sandborn WJ, Gasink C, Gao LL et al. Ustekinumab induction and maintenance therapy in refractory Crohn’s disease. N Engl J Med 2012; 367(16): 1519– 1528. doi: 10.1056/ NEJMoa1203572.

13. Cameron FL, Gar­rick V, Rus­sell RK. Ustekinumab in treatment of refractory paediatric crohn disease. J Pediatr Gastroenterol Nutr 2016; 62(3): e30. doi: 10.1097/ MPG.0000000000000608.

14. Bishop C, Simon H, Suskind D et al. Ustekinumab in pediatric Crohn disease patients. J Pediatr Gastroenterol Nutr 2016; 63(3): 348– 351. doi: 10.1097/ MPG.0000000000001146.

15. Rinawi F, Rosenbach Y, As­sa A et al. Ustekinumab for resistant pediatric Crohn disease. J Pediatr Gastroenterol Nutr 2016; 62(4): e34– e35. doi: 10.1097/ MPG.00 00000000000503.

16. Shale MJ, Riley SA. Studies of compliance with delayed-release mesalazine therapy in patients with inflam­matory bowel disease. Aliment Pharmacol Ther 2003; 18(2): 191– 198.

17. Gear­ry RB, Barclay ML. Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitor­ing in inflam­matory bowel disease. J Gastroenterol Hepatol 2005; 20(8): 1149– 1157.

18. Roter DL, Hall JA, Merisca R et al. Ef­fectiveness of interventions to improve patient compliance: a meta-analysis. Med Care 1998; 36(8): 1138– 1161.

19. Bernal I, Domènech E, Garcia-Planel­la E et al. Medication-tak­ing behavior in a cohort of patients with inflam­matory bowel disease. Dig Dis Sci 2006; 51(12): 2165– 2169.

20. Levine A, Turner D. Combined azithromycin and metronidazole therapy is ef­fective in induc­ing remis­sion in pediatric Crohn’s disease. J Crohns Colitis 2011; 5(3): 222– 226. doi: 10.1016/ j.crohns.2011.01.006.

21. Turner D, Levine A, Kolho KL et al. Combination of oral antibio­tics may be ef­fective in severe pediatric ulcerative colitis: a preliminary report. J Crohns Colitis 2014; 8(11): 1464– 1470.

22. Fukuda Y, Matsui T, Suzuki Y et al. Adsorptive granulocyte and monocyte apheresis for refractory Crohn’s disease: an open multicenter prospective study. J Gastroenterol 2004; 39(12): 1158– 1164.

23. Cas­sinotti A, An­naloro C, Ardizzone Set al. Autologous haematopoietic stem cell transplantation without CD34+ cell selection in refractory Crohn’s disease. Gut 2008; 57(2): 211– 217.

24. Uhlig HH, Schwerd T, Koletzko S et al. The dia­gnostic approach to monogenic very early onset inflam­matory bowel dis­ease. Gastroenterology 2014; 147(5): 990– 1007. doi: 10.1053/ j.gastro.2014.07.023.

25. Miloh T, Bulut P. Primary scleros­ing cholangitis dur­ing childhood and adolescence. Clinical Liver Disease 2013; 2(5): 215– 218.

26. European As­sociation for the Study of the Liver. EASL Clinical Practice Guide­lines: management of cholestatic liver dis­eases. J Hepatol 2009; 51(2): 237– 267. doi: 10.1016/ j.jhep.2009.04.009.

27. Kerkar N, Miloh T. Scleros­ing cholangitis: pediatric perspective. Curr Gastroenterol Rep 2010; 12(3): 195– 202. doi: 10.1007/ s11894-010-0104-5.

28. Faubio­n WA Jr, Loftus EV, Sandborn WJet al. Pediatric "PSC-IBD": a descriptive report of as­sociated inflam­matory bowel disease among pediatric patients with psc. J Pediatr Gastroenterol Nutr 2001; 33(3): 296– 300.

29. Bajer L, Kamenář D, Sticová E et al. Idiopatický střevní zánět u pa­cientů s primární sklerozující cholangitidou –  samostatný fenotyp IBD. Gastroent Hepatol 2014; 68(1): 24– 35.

30. Ros­si G, Sciveres M, Maruzzel­li L et al. Dia­gnosis of scleros­ing cholangitis in child­ren: blinded, comparative study of magnetic resonance versus endoscopic cholangiography. Clin Res Hepatol Gastroenterol 2013; 37(6): 596– 601. doi: 10.1016/ j.clinre. 2013.05.014.

31. Mamula P, Markowitz JE, Baldas­sano RN(eds). Pediatric inflam­matory bowel dis­ease. 2nd ed. New York: Springer-Verlag 2013: 592.

32. Dezsőfi A, Baumann U, Dhawan A et al. Liver bio­psy in children: position paper of the ESPGHAN Hepatology Com­mittee. J Pediatr Gastroenterol Nutr 2015; 60(3): 408– 420. doi: 10.1097/ MPG.000000 0000000632.

33. Hom­mes DW, Erkelens W, Ponsioen C et al. A double-blind, placebo-control­led, randomized study of infliximab in primary scleros­ing cholangitis. J Clin Gastroenterol 2008; 42(5): 522– 526. doi: 10.1097/ MCG.0b013e3181662426.

34. Lindor KD, Kowdley KV, Luketic VA et al. High-dose ursodeoxycholic acid for the treatment of primary scleros­ing cholangitis. Hepatology 2009; 50(3): 808– 814. doi: 10.1002/ hep.23082.

35. Nevoral J. Praktická pediatrická gastroenterologie, hepatologie a výživa. Praha: Mladá fronta 2013: 677.

36. Dhawan A (ed). Concise pediatric and adolescent hepatology. London: Karger 2012: 264.

37. Tabibian JH, Weed­ing E, Jorgensen RA et al. Randomised clinical trial: vancomycin or metronidazole in patients with primary scleros­ing cholangitis –  a pilot study. Aliment Pharmacol Ther 2013; 37(6): 604– 612. doi: 10.1111/ apt.12232.

38. Abarbanel DN, Seki SH, Davies Y et al. Im­munomodula­tory ef­fect of vancomycin on Treg in pediatric inflam­matory bowel dis­ease and primary scleros­ing cholangitis. J Clin Im­munol 2013; 33(2): 397– 406. doi: 10.1007/  s10875-012-9801-1.

39. Davies YK, Cox KM, Abdul­lah BA et al. Long-term treatment of primary scleros­ing cholangitis in children with oral vancomycin: an im­munomodulat­ing antibio­tic. J Pediatr Gastroenterol Nutr 2008; 47(1): 61– 67. doi: 10.1097/ MPG.0b013e31816fee95.

40. Ibrahim SH, Lindor KD. Cur­rent management of primary scleros­ing cholangitis in pediatric patients. Paediatr Drugs 2011; 13(2): 87– 95. doi: 10.2165/ 11586500-000000000-00000.

41. Rahier F, Magro F, Abreu C et al. Second European evidence-based consensus on the prevention, dia­gnosis and man­agement of opportunistic infections in inflam­matory bowel disease. J Crohns Colitis 2014; 8(6): 443– 468. doi: 10.1016/ j.crohns.2013.12.013.

42. Veereman-Wauters G, de Ridder L, Ve­res G et al. Risk of infection and prevention in pediatric patients with IBD: ESPGHAN IBD Porto Group com­mentary. J Pe-diatr Gastroenterol Nutr 2012. 54(6): 830––837. doi: 10.1097/ MPG.0b013e31824d 1438.

43. Zitomersky NL, Verhave M, Trenor CC3rd. Thrombosis and inflam­matory bowel disease: a call for improved awareness and prevention. Inflamm Bowel Dis 2011; 17(1): 458– 470. doi: 10.1002/ ibd.21334.

44. Rosendaal FR, Helmerhorst FM, Vandenbroucke JP. Female hormones and thrombosis. Arterioscler Thromb Vasc Biol 2002; 22(2): 201– 210.

45. Nylund CM, Goudie A, Garza JM et al. Venous thrombotic events in ho­spita­l­­-ized children and adolescents with inflam­matory bowel disease. J Pediatr Gastroenterol Nutr 2013; 56(5): 485– 491. doi: 10.1097/ MPG.0b013e3182801e43.

46. Blickstein D, Blickstein I. Oral contraception and thrombophilia. Curr Opin Obstet Gynecol 2007; 19(4): 370– 376.

47. Nguyen GC, Bernstein CN, Bitton A et al. Consensus statements on the risk, prevention, and treatment of venous thromboembolism in inflam­matory bowel disease: Canadian As­sociation of Gastroenterology. Gastroenterology 2014; 146(3): 835– 848. doi: 10.1053/ j.gastro.2014.01.042.

Štítky
Paediatric gastroenterology Gastroenterology and hepatology Surgery

Článok vyšiel v časopise

Gastroenterology and Hepatology

Číslo 1

2017 Číslo 1
Najčítanejšie tento týždeň
Najčítanejšie v tomto čísle
Prihlásenie
Zabudnuté heslo

Zadajte e-mailovú adresu, s ktorou ste vytvárali účet. Budú Vám na ňu zasielané informácie k nastaveniu nového hesla.

Prihlásenie

Nemáte účet?  Registrujte sa

#ADS_BOTTOM_SCRIPTS#